Business
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of
About this update from Immunitybio, Inc.
[{"type":"text","content":"\nImmunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) \n\n\n\nVaccine Vector to Protect Against SARS-CoV-2 Infection:\n\n\nImmunityBio’s Ad5: A second -generation adenovirus vaccine platform with four deletions enabling multiple homologous doses, even in patients with adenovirus immunity\n\n\n\n\n\n\nTherapeutic Immunomodulators for Patients with Mild to Moderate COVID-19 Symptoms:\n\n\nNantKwest’s haNK: CD-16, off-the-shelf natural killer cells to enhance antibody killing of infected cells, given alone or combined with Convalescent Plasma (CP)\n\n\nImmunityBio’s N-803: Interleukin 15 (IL-15) ‘superagonist’ cytokine to stimulate natural killer cells and CD8+ T cells\n\n\n\n\n\n\nTherapeutic for Severe and Critically Ill COVID-19 Patients on Ventilator Support:\n\n\nNantKwest’s MSCs: Bone marrow-derived mesenchymal stem cells (MSC) to mitigate ‘cytopathic storm’\n\n\n\n\n EL SEGUNDO, Calif.--(BUSINESS WIRE)--\nNantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., clinical-stage immunotherapy companies within the NantWorks family of companies, today announced they are in active discussions with the U.S. Food and Drug Administration (FDA) for vaccines and therapeutics to combat COVID-19.\n\n\nLeveraging ImmunityBio’s expertise in vaccine development and natural killer cell activation, with a broad platform of immunomodulators currently in clinical trials for cancer and infectious diseases, and NantKwest’s extensive experience in off-the-shelf, cell-based therapeutics, the companies are combining their resources to design and develop therapeutics and vaccines for COVID-19.\n\n\n“We’re in a race against time, but I am confident that, as a result of the incredible hard work the NantKwest, ImmunityBio, and the global scientific communities are undertaking, we will find effective therapeutics and vaccines against this coronavirus,” said Patrick Soon-Shiong, M.D., Chairman & CEO of NantKwest and ImmunityBio.\n\n\nTherapeutics:\n\n\nThe biological, immunological, and physiological status of the patient’s medical state should inform the treatment strategy to reverse the infectivity and tissue damage caused by this virus. ImmunityBio and NantKwest have develope...